Urologic Oncology: Seminars and Original Investigations This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Cover 2 - Masthead
(Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - December 8, 2018 Category: Urology & Nephrology Source Type: research

Editorial Board
(Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - December 8, 2018 Category: Urology & Nephrology Source Type: research

Table of Contents
(Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - December 8, 2018 Category: Urology & Nephrology Source Type: research

Molecular tumor heterogeneity in muscle invasive bladder cancer: Biomarkers, subtypes, and implications for therapy
The objective of this review is to dissect recent insights into inter- and intratumor heterogeneity (ITH) in MIBC, with emphasis on the clinical implications of this heterogeneity for biomarker-driven strategies and the development of new therapies. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - December 8, 2018 Category: Urology & Nephrology Authors: Jose Batista da Costa, Ewan A. Gibb, Timo K. Nykopp, Miles Mannas, Alexander W. Wyatt, Peter C. Black Tags: Seminars Article Source Type: research

Introduction to the seminar series: Optimal management during ADT to mitigate complications
In this special edition of Urologic Oncology, we are addressing the effects of androgen deprivation therapy (ADT) for men with prostate cancer. The contributors to this edition were invited based their areas of expertise and willingness to present updated and practical information for providers involved in the care of prostate cancer patients. Drs. Melloni and Roe present current data on androgen deprivation therapy and cardiovascular disease. Management of bone and metabolic effects is reviewed by Drs. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - December 7, 2018 Category: Urology & Nephrology Authors: Celestia S. Higano Tags: Seminars article Source Type: research

The impact of statins in combination with androgen deprivation therapyin patients with advanced prostate cancer: A large observational study
Statins are one of the most commonly prescribed medications for hypercholesterolemia worldwide, with 1 in 4 Americans over 45 taking a daily statin [1]. Statins lower cholesterol levels by inhibiting the 3-hydroxy-3-methylglutaryl-coenzyme A enzyme at the rate limiting step in the mevalonate pathway of cholesterol synthesis [2]. Recent research has focused on the antineoplastic role of statins through their impact on cell proliferation, inflammation, membrane organization, and steroidogenesis [3]. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - December 7, 2018 Category: Urology & Nephrology Authors: India Anderson-Carter, Natasza Posielski, Jinn-ing Liou, Tariq A. Khemees, Tracy M. Downs, E. Jason Abel, David F. Jarrard, Kyle A. Richards Tags: Clinical-Prostate cancer Source Type: research

Effect of PD-L1 testing on the cost-effectiveness and budget impact of pembrolizumab for advanced urothelial carcinoma of the bladder in the United States
Our purpose was to evaluate the effect of PD-L1 testing on the cost-effectiveness of pembrolizumab for second-line treatment of advanced urothelial carcinoma in the bladder from the U.S. societal perspective. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - December 6, 2018 Category: Urology & Nephrology Authors: Steven D. Criss, Davis T. Weaver, Deirdre F. Sheehan, Richard J. Lee, Pari V. Pandharipande, Chung Yin Kong Tags: Clinical-Bladder cancer Source Type: research

Reducing unnecessary biopsies while detecting clinically significant prostate cancer including cribriform growth with the ERSPC Rotterdam risk calculator and 4Kscore
Prostate Specific Antigen (PSA)-based prostate cancer (CaP) screening is beneficial in terms of mortality reduction, however its main drawbacks are overdiagnosis and overtreatment of indolent CaP [1]. A more and more used strategy to limit overtreatment of indolent CaP cancer is the use of active surveillance as initial treatment [2]. To improve screening efforts further, a balance must be found between minimizing overdiagnosis, and optimizing the timely detection of potentially deadly disease [3]. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - December 6, 2018 Category: Urology & Nephrology Authors: Jan F.M. Verbeek, Chris H. Bangma, Charlotte F. Kweldam, Theodorus H. van der Kwast, Intan P. K ümmerlin, Geert J.L.H. van Leenders, Monique J. Roobol Tags: Clinical-Prostate cancer Source Type: research

Renal cell carcinoma and brain metastasis: Questioning the dogma of role for cytoreductive nephrectomy
The increased utilization of cross-sectional imaging is at least partially responsible for the growing incidence of renal cell carcinoma (RCC) throughout the last 30 years. It has been estimated for 2018 that approximately 65,340 new patients will be diagnosed with RCC, over 60% incidentally, and about 14,970 patients will die from RCC [1]. Even with the increased detection of incidental renal masses, approximately 30% of patients still present with metastatic disease [2]. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - December 5, 2018 Category: Urology & Nephrology Authors: Michael Daugherty, Emily Daugherty, Joseph Jacob, Oleg Shapiro, Mehdi Mollapour, Gennady Bratslavsky Source Type: research

Proton therapy for prostate cancer: A review of the rationale, evidence, and current state
Men diagnosed with localized prostate cancer have many curative treatment options including several different radiotherapeutic approaches. Proton radiation is one such radiation treatment modality and, due to its unique physical properties, offers the appealing potential of reduced side effects without sacrificing cancer control. In this review, we examine the intriguing dosimetric rationale and theoretical benefit of proton radiation for prostate cancer and highlight the results of preclinical modeling studies. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - December 4, 2018 Category: Urology & Nephrology Authors: Trevor J. Royce, Jason A. Efstathiou Tags: Seminars article Source Type: research

Re: “Monopolar vs. bipolar transurethral resection for nonmuscle invasive bladder carcinoma: A post hoc analysis from a randomized controlled trial”
The authors have published a valuable article that compares safety and efficacy between monopolar transurethral resection of bladder (mTURB) and bipolar (bTURB) for patients with primary nonmuscle invasive bladder cancer. They have found no evident advantages of bTURB over mTURB with respect to operation time, perioperative and postoperative complication rates, and recurrence rates at 12 months [1]. The mainstay for the diagnosis and initial treatment of bladder cancer is TURBT, aiming at reaching a definitive diagnosis and removing all visible lesions including a part of underlying muscle [2]. (Source: Urologic Oncology: ...
Source: Urologic Oncology: Seminars and Original Investigations - December 4, 2018 Category: Urology & Nephrology Authors: Bulent Gunlusoy, Deniz Bolat, Tansu Degirmenci Tags: Letter to the Editor Source Type: research

Role of serum cholinesterase in patients treated with salvage radical prostatectomy
Serum cholinesterase (ChE) a serine hydrolase that catalyses the hydrolysis of esters of choline, is involved in cellular proliferation and differentiation, therefore affecting carcinogenesis. The aim of this study was to understand the prognostic role of preoperative serum ChE in patients with radiation-recurrent prostate cancer (CaP) treated with salvage radical prostatectomy (SRP). (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - December 3, 2018 Category: Urology & Nephrology Authors: Mihai Dorin Vartolomei, David D'Andrea, Daher C. Chade, Francesco Soria, Shoji Kimura, Beat Foerster, Mohammad Abufaraj, Romain Mathieu, Marco Moschini, Morgan Roupr êt, Alberto Briganti, Pierre I. Karakiewicz, Shahrokh F. Shariat Tags: Original Article Source Type: research

Analyzing the current practice patterns and views among urologists regarding focal therapy for prostate cancer
The widespread use of prostate-specific antigen screening has led to an earlier and increased diagnosis of low-risk prostate cancer (CaP) [1,2]. While urologists have increasingly been using active surveillance for very low-risk and low-risk disease, whole gland treatment (WGT) by means of radical prostatectomy and radiation therapy is still widely used for high volume low-risk and low volume intermediate-risk CaP. However, the risk of CaP mortality in these populations is low [3,4]. These patients may ultimately receive WGT because of several reasons, including, but not limited to, concerns of the patient and physician, y...
Source: Urologic Oncology: Seminars and Original Investigations - December 3, 2018 Category: Urology & Nephrology Authors: Amit L. Jain, Abhinav Sidana, Mahir Maruf, Dordaneh Sugano, Brian Calio, Bradford J. Wood, Peter A. Pinto Tags: Clinical-Prostate cancer Source Type: research

Cover 2 -- Masthead
(Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - December 1, 2018 Category: Urology & Nephrology Source Type: research

Editorial Board
(Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - December 1, 2018 Category: Urology & Nephrology Source Type: research